TITLE:
Could Surgery Improve Survival in Patients with Advanced Endometrial Cancer?
AUTHORS:
Mervat Ali Mohamed Elsersy
KEYWORDS:
Endometrial Cancer, Chemotherapy, Survival, Upfront Surgery, Radiotherapy
JOURNAL NAME:
Open Journal of Obstetrics and Gynecology,
Vol.12 No.8,
August
25,
2022
ABSTRACT: Background: Patients with endometrial cancer are mostly diagnosed at an early stage.
But unfortunately 10% to 15% of endometrial cancer patients will present with
advanced-stage disease, and hence poorer prognosis. When disease is primarily
intraperitoneal, cytoreduction to reduced to no visible disease remaining. Aim: Of the work is to detect the survival rate benefits of primary surgery
in patients with advanced endometrial cancer at gynecologic oncology unit in El
Shatby Maternity University Hospital. Methods and Materials: Retrospective study was conducted on 102 patients diagnosed to have advanced
endometrial cancer FIGO (stage III/IV) in a duration of 4 years between 2016
and 2020 and had undergone cytoreductive surgery. The patients were further subdivided
into two groups: group 1 who underwent optimal cytoreduction with residual
disease less than or equal 1 cm visible lesion, and group 2 who had residual disease more than 1 cm visible
lesion and they were followed to check the survival benefits. Results: The
mean of disease free survival in group: 1) patients was 2 years which was
significantly longer than those in group; 2) those who had residual disease > 1 cm, p I endometrial cancer had significantly longer (DFS) than those diagnosed to have type II endometrial
cancer, p = 0.046. Conclusion: Primary
complete cytoreductive (upfront) surgery when possible has a favorable
impact on overall survival in patients with advanced endometrial cancer.